{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:08:11Z","timestamp":1788786491831,"version":"build-2803163510"},"reference-count":42,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210053"],"award-info":[{"award-number":["JP20fk0210053"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0310103"],"award-info":[{"award-number":["JP20fk0310103"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210072"],"award-info":[{"award-number":["JP20fk0210072"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210056"],"award-info":[{"award-number":["JP20fk0210056"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0310101"],"award-info":[{"award-number":["JP20fk0310101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210067"],"award-info":[{"award-number":["JP20fk0210067"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"award":["JP20fk0210053"],"award-info":[{"award-number":["JP20fk0210053"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP20fk0310103"],"award-info":[{"award-number":["JP20fk0310103"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP20fk0210072"],"award-info":[{"award-number":["JP20fk0210072"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP20fk0210056"],"award-info":[{"award-number":["JP20fk0210056"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP20fk0310101"],"award-info":[{"award-number":["JP20fk0310101"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP20fk0210067"],"award-info":[{"award-number":["JP20fk0210067"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP20K08371"],"award-info":[{"award-number":["JP20K08371"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP25K14859"],"award-info":[{"award-number":["JP25K14859"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP19K18956"],"award-info":[{"award-number":["JP19K18956"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"award":["JP20K08371"],"award-info":[{"award-number":["JP20K08371"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP25K14859"],"award-info":[{"award-number":["JP25K14859"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP19K18956"],"award-info":[{"award-number":["JP19K18956"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease worldwide, and effective pharmacological therapies remain limited. Pemafibrate (Pema), a selective peroxisome proliferator-activated receptor alpha (PPAR\u03b1) modulator (SPPARM\u03b1), has shown promising therapeutic potential in patients with MASLD and hypertriglyceridemia; however, its underlying mechanisms remain incompletely understood. Here, we investigated the therapeutic effects and molecular mechanisms of Pema using in vitro and in vivo MASLD models and evaluated its clinical relevance in patients with MASLD. In a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-induced MASLD mouse model, Pema dose-dependently ameliorated hepatic steatosis and fibrosis and significantly suppressed the hepatic expression of inflammatory and fibrogenic genes, including TLR4, TNF\u03b1, \u03b1SMA, and Col1A1. Pema also favorably altered the gut microbiota by increasing the abundance of the phylum Verrucomicrobia, suggesting modulation of the gut\u2013liver axis. In differentiated 3T3-L1 adipocyte-like cells, Pema induced PPAR\u03b1 expression, inhibited insulin-mediated EGR-1 induction, and significantly reduced leptin secretion. Consistent with these findings, serum insulin and leptin levels, as well as the hepatic accumulation of both molecules, were markedly decreased in Pema-treated MASLD mice. Furthermore, in a clinical cohort of 192 patients with MASLD and hypertriglyceridemia, long-term Pema treatment significantly improved liver-related biochemical parameters, insulin resistance, surrogate markers of liver fibrosis, and serum leptin levels. Collectively, these findings demonstrate that Pema attenuates MASLD progression by suppressing leptin-mediated metabolic and inflammatory signaling while improving the gut microenvironment. These results highlight SPPARM\u03b1 as a promising therapeutic strategy for MASLD and support further clinical investigation of Pema as a disease-modifying treatment targeting the gut\u2013liver axis.<\/jats:p>","DOI":"10.3390\/ijms27177611","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:27:19Z","timestamp":1787657239000},"page":"7611","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective PPAR\u03b1 Modulator Pemafibrate Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Regulation of Leptin Signaling and Remodeling of Gut Microbiota"],"prefix":"10.3390","volume":"27","author":[{"given":"Koji","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"},{"name":"Department of Physiology, Asahikawa Medical University, Asahikawa 078-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, JCHO Hokkaido Hospital, Sapporo 062-8618, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"},{"name":"Keijinkai Maruyama Clinic, Sapporo 064-0820, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"},{"name":"Department of Gastroenterology, Sapporo City General Hospital, Sapporo 060-8604, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"},{"name":"Department of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Asahikawa 070-8530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3891-5113","authenticated-orcid":false,"given":"Kenichi","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"},{"name":"Keimei Clinic, Sapporo 064-0913, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sho","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"},{"name":"Department of Gastroenterology, NTT Medical Center Sapporo Hospital, Sapporo 060-0061, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Furuya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, JCHO Hokkaido Hospital, Sapporo 062-8618, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-059X","authenticated-orcid":false,"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.21037\/atm.2016.08.54","article-title":"Hepatitis B: Progress in understanding chronicity, the innate immune response, and cccDNA protection","volume":"4","author":"Morikawa","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/hepr.12650","article-title":"Viral life cycle of hepatitis B virus: Host factors and druggable targets","volume":"46","author":"Morikawa","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/hepr.13768","article-title":"Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients","volume":"52","author":"Umemura","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2147\/DDDT.S133697","article-title":"Safety and efficacy of elbasvir\/grazoprevir for the treatment of chronic hepatitis C: Current evidence","volume":"12","author":"Morikawa","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","article-title":"Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C","volume":"51","author":"Suda","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00535-017-1427-x","article-title":"Treatment of hepatitis C in special populations","volume":"53","author":"Suda","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/hepr.14047","article-title":"Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021","volume":"54","author":"Enomoto","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.jhep.2023.09.038","article-title":"From NAFLD to MASLD: Promise and pitfalls of a new definition","volume":"81","author":"Cusi","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/jgh3.12349","article-title":"Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review","volume":"4","author":"Eguchi","year":"2020","journal-title":"JGH Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14656566.2024.2374463","article-title":"Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: Where are we today?","volume":"25","author":"Puengel","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.medj.2024.03.013","article-title":"Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?","volume":"5","year":"2024","journal-title":"Med"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Qasim, A., Alataa, R., Veena, F., and Shehi, E. (2026). The new era of MASH pharmacotherapy: A comprehensive review of FDA-approved and emerging agents. Front. Gastroenterol., 5.","DOI":"10.3389\/fgstr.2026.1850915"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPARalpha modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., and Kodama, T. (2019). Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor alpha Modulator (SPPARMalpha) Pemafibrate. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225682"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/hepr.13571","article-title":"Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study","volume":"50","author":"Seko","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of Pemafibrate, a Novel Selective PPARalpha Modulator, on Lipid and Glucose Metabolism in Patients with Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e13057","DOI":"10.1002\/jgh3.13057","article-title":"Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study","volume":"8","author":"Ono","year":"2024","journal-title":"JGH Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.20896","article-title":"Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease","volume":"42","author":"Musso","year":"2005","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/jhep.2002.34738","article-title":"Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity?","volume":"36","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eaau9685","DOI":"10.1126\/scisignal.aau9685","article-title":"Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice","volume":"12","author":"Oakley","year":"2019","journal-title":"Sci. Signal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1254\/fpj.129.271","article-title":"Candidate drugs for non-alcoholic steatohepatitis (NASH)","volume":"129","author":"Terai","year":"2007","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"753917","DOI":"10.1155\/2011\/753917","article-title":"Atherogenic omega-6 Lipids Modulate PPAR- EGR-1 Crosstalk in Vascular Cells","volume":"2011","author":"Fei","year":"2011","journal-title":"PPAR Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.12659\/MSM.914044","article-title":"Transcriptional Regulation of Early Growth Response Gene-1 (EGR1) is Associated with Progression of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Insulin Resistance","volume":"25","author":"Li","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"23816","DOI":"10.1038\/s41598-024-74340-5","article-title":"Selective activation of PPARalpha by pemafibrate mitigates peritoneal inflammation and fibrosis through suppression of NLRP3 inflammasome and modulation of inflammation","volume":"14","author":"Shinkai","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e70135","DOI":"10.14814\/phy2.70135","article-title":"Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice","volume":"13","author":"Takahara","year":"2025","journal-title":"Physiol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdermsci.2020.05.005","article-title":"Selective PPARalpha agonist pemafibrate inhibits TNF-alpha-induced S100A7 upregulation in keratinocytes","volume":"99","author":"Yumine","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_33","first-page":"345","article-title":"Overexpression of EGR-1 modulates the activity of NF-kappaB and AP-1 in prostate carcinoma PC-3 and LNCaP cell lines","volume":"39","author":"Parra","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_34","first-page":"847","article-title":"Inhibition of Egr-1 by siRNA in prostate carcinoma cell lines is associated with decreased expression of AP-1 and NF-kappaB","volume":"28","author":"Parra","year":"2011","journal-title":"Int. J. Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.emboj.7600501","article-title":"NF-kappaB\/Egr-1\/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death","volume":"24","author":"Thyss","year":"2005","journal-title":"EMBO J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/hepr.13757","article-title":"The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease","volume":"52","author":"Nakamura","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.1128\/AEM.01477-07","article-title":"Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly","volume":"73","author":"Collado","year":"2007","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.micpath.2016.02.005","article-title":"Akkermansia muciniphila and its role in regulating host functions","volume":"106","author":"Derrien","year":"2017","journal-title":"Microb. Pathog."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1099\/ijs.0.02873-0","article-title":"Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium","volume":"54","author":"Derrien","year":"2004","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ashrafian, F., Shahriary, A., Behrouzi, A., Moradi, H.R., Keshavarz Azizi Raftar, S., Lari, A., Hadifar, S., Yaghoubfar, R., Ahmadi Badi, S., and Khatami, S. (2019). Akkermansia muciniphila-Derived Extracellular Vesicles as a Mucosal Delivery Vector for Amelioration of Obesity in Mice. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02155"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ottman, N., Reunanen, J., Meijerink, M., Pietila, T.E., Kainulainen, V., Klievink, J., Huuskonen, L., Aalvink, S., Skurnik, M., and Boeren, S. (2017). Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173004"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"117067","DOI":"10.1016\/j.biopha.2024.117067","article-title":"Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition","volume":"177","author":"Bentanachs","year":"2024","journal-title":"Biomed. Pharmacother."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7611\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:13:11Z","timestamp":1788783191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":42,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177611"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177611","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}